MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Anxiety"

  • 2023 International Congress

    Effects of Motor Subtype Stability on Non-Motor Symptoms in Early Parkinson’s Disease

    S. Ng, N. Chia, X. Choi, D. Heng, S. Neo, ZY. Xu, KY. Tay, WL. Au, EK. Tan, L. Tan (Singapore, Singapore)

    Objective: To determine the effects of motor subtypes’ stability on non-motor symptoms (NMS) over three years in early Parkinson’s disease (PD). Background: Research have found…
  • 2023 International Congress

    Anxiety in Parkinson’s disease is associated with changes in brain structural connectivity

    G. Carey, R. Viard, R. Lopes, G. Kuchcinski, L. Defebvre, A. Leentjens, K. Dujardin (Lille, France)

    Objective: The aim of this study was to identify White Matter (WM) changes by comparing Parkinson's disease (PD) patients with and without anxiety, using diffusion-tensor…
  • 2023 International Congress

    Genetic and psychiatric risk factors for impulse control disorders in de novo Parkinson’s disease

    M. Ruitenberg, E. Whooley, H. Macdonald, V. Koppelmans (Leiden, Netherlands)

    Objective: To assess the interplay of polygenic dopamine risk scores and psychiatric symptoms in the development of impulse control disorders (ICDs) in de novo patients…
  • 2023 International Congress

    Psilocybin therapy for depression and anxiety associated with Parkinson’s disease: a pilot study (NCT04932434)

    E. Bradley, K. Sakai, G. Fernandes, C. Ludwig, M. Bock, J. Ostrem, C. Tanner, A. O'Donovan, P. Finley, Z. Busby, A. Mckernan, R. Zuzuarregui, A. Penn, A. Wang, A. Theberge, R. Rosen, J. Woolley (San Francisco, USA)

    Objective: To investigate the safety, tolerability, feasibility, and preliminary efficacy of moderate and high dose psilocybin treatment with psychotherapeutic support for comorbid Parkinson's disease (PD)…
  • 2023 International Congress

    The impact of anxiety symptoms and treatment on Parkinson’s disease-related disability: findings from the Parkinson’s Progression Markers Initiative

    N. Dahodwala, D. Weintraub, M. Bock, R. Cho, C. Caspell-Garcia, E. Brown, R. Dobkin (Philadelphia, USA)

    Objective: To determine the functional consequences of baseline anxiety symptoms and the longer-term impact of initiation of anxiety treatment in Parkinson’s disease (PD). Background: While…
  • 2023 International Congress

    Healthcare experiences of People with Parkinson’s Disease (PwP) during COVID-19 pandemic

    V. Tomantschger, A. Tautscher-Basnett, C. Hohenwarter (Hermagor, Austria)

    Objective: To investigate how our group of PwP coped with healthcare issues during the pandemic. Background: COVID-19 pandemic led to changes in how healthcare services…
  • 2023 International Congress

    Dynamic assessment of levels of depression and anxiety impairment in Parkinson’s disease

    O. Naimov, R. Matmurodov (Tashkent, Uzbekistan)

    Objective: To dynamic assessment of depression and anxiety disorders in Parkinson's disease. Background: One of the most common nonmotor disturbances in Parkinson's disease (PD) is…
  • 2022 International Congress

    Relation of affective disorders and quality of life in the chronic pain of disease Parkinson’s patients

    K. Stepanchenko, A. Jidkova (Kharkiv, Ukraine)

    Objective: To study affective disorders and their impact on the quality of life in patients with PD and chronic pain syndrome. Background: Mechanisms of the…
  • 2022 International Congress

    Parkinson’s disease caregiver burden in rural India

    S. Desai, D. Desai, I. Prashnani (Anand, India)

    Objective: To assess the caregiver burden and factors determining it in patients with PD. To assess the anxiety and depression amongst caregivers. Background: Patients with…
  • 2022 International Congress

    The reasons for referral to a Parkinson’s Clinical Psychology service

    R. Lewis-Morton, B. Mohamed, E. Thomas, S. Mahon, T. Williams (Cardiff, United Kingdom)

    Objective: To understand the reasons for referral to a Parkinson's Clinical Psychology service. Background: In recent times, the psychological impact of Parkinson’s Disease has become…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 17
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley